Seres Therapeutics: Pay

Seres Therapeutics paid its 5 named executives $6.1M in total in FY2025 (Dec).

Pay of each named executive

Eric D. ShaffFormer President and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years
Thomas J. DesRosierFormer Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Marella ThorellFormer Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer
FY2025 (Dec)
1 year
Teresa L. Young, Ph.D.Former Executive Vice President and Chief Commercial and Strategy Officer
FY2025 (Dec)
FY2023 (Dec)
2 years
Matthew Henn, Ph.D.President and Chief Scientific Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 5 peers with pay on file was $4.2M. CEO pay of Seres Therapeutics for that year is not on file.

  1. 1Mirum Pharmaceuticals
  2. 2Travere Therapeutics
  3. 3Atea Pharmaceuticals
  4. 4Arcutis Biotherapeutics
  5. 5Enanta Pharmaceuticals
  6. 6Seres TherapeuticsNot disclosed
  7. 7Amylyx PharmaceuticalsNot disclosed
  8. 8ArdelyxNot disclosed
  9. 9Atara Biotherapeutics Inc.Not disclosed
  10. 10Chinook Therapeutics, Inc.Not disclosed
  11. 11Collegium PharmaceuticalNot disclosed
  12. 12Crinetics Pharmaceuticals, Inc.Not disclosed
  13. 13Deciphera Pharmaceuticals, Inc.Not disclosed
  14. 14ImmunoGen, Inc.Not disclosed
  15. 15Ironwood PharmaceuticalsNot disclosed
  16. 16Karyopham Therapeutics, Inc.Not disclosed
  17. 17MacrogenicsNot disclosed
  18. 18Revance Therapeutics, Inc.Not disclosed
  19. 19Rhythm PharmaceuticalsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.